Hans Denison

Cost-effectiveness of ticagrelor plus aspirin versus aspirin in acute ischaemic stroke or transient ischaemic attack: an economic evaluation of the THALES trial

Amarjeet Tank, S. Claiborne Johnston, Ritika Jain, Pierre Amarenco et autres

Objective: THALES demonstrated that ticagrelor plus aspirin reduced the risk of stroke or death but increased bleeding versus aspirin during the 30 days following a mild-to-moderate acute non-cardioembolic ischaemic stroke (AIS) or high-risk transient ischaemic attack (TIA). There are no cost-effectiveness analyses …

gb, in, se, us, es, cn (code pays fourni par la source)

Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack

Yongjun Wang, Yuesong Pan, Hao Li, Pierre Amarenco et autres

BACKGROUND AND OBJECTIVES: The goal of this work was to investigate the short-term time-course benefit and risk of ticagrelor with aspirin in acute mild-moderate ischemic stroke or high-risk TIA in The Acute Stroke or Transient Ischemic Attack Treated with Ticagrelor and ASA …

fr, se, us, cn, es (code pays fourni par la source)

Ischemic Benefit and Hemorrhage Risk of Ticagrelor-Aspirin Versus Aspirin in Patients With Acute Ischemic Stroke or Transient Ischemic Attack

S. Claiborne Johnston, Pierre Amarenco, Maria Aunes, Hans Denison et autres

Background and Purpose: In patients with acute mild-moderate ischemic stroke or high-risk transient ischemic attack, the THALES trial (Acute Stroke or Transient Ischemic Attack Treated With Ticagrelor and Aspirin for Prevention of Stroke and Death) demonstrated that when added to aspirin, ticagrelor …

us, fr, fi, it, se, ru, es, de, cn (code pays fourni par la source)

Efficacy and Safety of Ticagrelor and Aspirin in Patients With Moderate Ischemic Stroke

Yongjun Wang, Yuesong Pan, Hao Li, Pierre Amarenco et autres

Importance: Prior trials of dual antiplatelet therapy excluded patients with moderate ischemic stroke. These patients were included in the Acute Stroke or Transient Ischaemic Attack Treated With Ticagrelor and ASA for Prevention of Stroke and Death (THALES) trial, but results have not …

pt, cn, fr, se, us, es (code pays fourni par la source)

PCV22 Estimating the Reduction in Medical Care Costs Associated with Ticagrelor and Aspirin in Patients with Acute Ischemic Stroke or TIA

Phil C. McEwan, Oliver T. Darlington, Mikael Knutsson, Hans Denison et autres

gb, se, fr, us (code pays fourni par la source)

Abstract MP4: Ticagrelor Plus Aspirin Versus Aspirin Alone in Acute Ischemic Stroke or TIA - Analysis of Bleeding Events in the THALES Trial

Carlos Alberto Molina, Pierre Amarenco, Per Ladenvall, Maria Aunes et autres

Introduction: In the THALES trial, ticagrelor and aspirin was superior to aspirin alone in reducing the primary endpoint of stroke or death, and subsequent disabling strokes, but increased risk of bleeding, as expected for dual antiplatelet therapy. Aim: Present the bleeding profile …

fr, se, us, de, cn (code pays fourni par la source)

Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin

Pierre Amarenco, Hans Denison, Scott R. Evans, Anders Himmelmänn et autres

Background and Purpose: Among patients with a transient ischemic attack or minor ischemic strokes, those with ipsilateral atherosclerotic stenosis of cervicocranial vasculature have the highest risk of recurrent vascular events. Methods: In the double-blind THALES (The Acute Stroke or Transient Ischemic Attack …

fr (code pays fourni par la source)

Ticagrelor Added to Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack in Prevention of Disabling Stroke

Pierre Amarenco, Hans Denison, Scott R. Evans, Anders Himmelmänn et autres

IMPORTANCE: Reduction of subsequent disabling stroke is the main goal of preventive treatment in the acute setting after transient ischemic attack (TIA) or minor ischemic stroke. OBJECTIVE: To evaluate the superiority of ticagrelor added to aspirin in preventing disabling stroke and to …

pt, fr, se, us, es, cn (code pays fourni par la source)

Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA

S. Claiborne Johnston, Pierre Amarenco, Hans Denison, Scott R. Evans et autres

BACKGROUND: Trials have evaluated the use of clopidogrel and aspirin to prevent stroke after an ischemic stroke or transient ischemic attack (TIA). In a previous trial, ticagrelor was not better than aspirin in preventing vascular events or death after stroke or TIA. …

us, fr, it, se, es, cn (code pays fourni par la source)

Methodologies for pragmatic and efficient assessment of benefits and harms: Application to the SOCRATES trial

Scott R. Evans, Mikael Knutsson, Pierre Amarenco, Gregory W. Albers et autres

Background/Aims: Standard approaches to trial design and analyses can be inefficient and non-pragmatic. Failure to consider a range of outcomes impedes evidence-based interpretation and reduces power. Traditional approaches synthesizing information obtained from separate analysis of each outcome fail to incorporate associations between …

us, se, gb, jp, es, cn, hk (code pays fourni par la source)

Disability after minor stroke and TIA

Brett L. Cucchiara, Donna Kurowski George, Scott Eric Kasner, Mikael Knutsson et autres

Objective To examine factors associated with disability following TIA and minor stroke, including poststroke complications such as stroke recurrence, major bleeding, and other adverse medical events. Methods The SOCRATES trial randomized patients with TIA/minor stroke (NIH Stroke Scale [NIHSS] score ≤5) within …

fr (code pays fourni par la source)

Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial

J. Donald Easton, Hans Denison, Scott R. Evans, Mikael Knutsson et autres

BACKGROUND: Adjudication of endpoints is a standard procedure in cardiovascular clinical trials. However, several studies indicate that the benefit of adjudication in estimating treatment effect may be limited. AIMS: This post hoc analysis of SOCRATES (NCT01994720) compared the treatment effects and investigated …

us, se, jp, es, cn, hk (code pays fourni par la source)